IMC Stock Overview
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Immuron Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.10 |
| 52 Week High | AU$0.17 |
| 52 Week Low | AU$0.065 |
| Beta | 1.14 |
| 1 Month Change | 2.04% |
| 3 Month Change | 33.33% |
| 1 Year Change | 26.58% |
| 3 Year Change | -44.44% |
| 5 Year Change | -50.00% |
| Change since IPO | -99.00% |
Recent News & Updates
Recent updates
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
Mar 08
We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Jan 20We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Oct 01We Think Immuron (ASX:IMC) Can Afford To Drive Business Growth
Mar 30Have Insiders Been Selling Immuron Limited (ASX:IMC) Shares This Year?
Feb 05
Shareholder Returns
| IMC | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | -4.8% | -3.0% | -2.2% |
| 1Y | 26.6% | -9.0% | 4.5% |
Return vs Industry: IMC exceeded the Australian Biotechs industry which returned -9% over the past year.
Return vs Market: IMC exceeded the Australian Market which returned 4.5% over the past year.
Price Volatility
| IMC volatility | |
|---|---|
| IMC Average Weekly Movement | 30.3% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in AU Market | 17.6% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: IMC's share price has been volatile over the past 3 months.
Volatility Over Time: IMC's weekly volatility has increased from 18% to 30% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 6 | Steve Lydeamore | www.immuron.com.au |
Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver.
Immuron Limited Fundamentals Summary
| IMC fundamental statistics | |
|---|---|
| Market cap | AU$22.80m |
| Earnings (TTM) | -AU$3.88m |
| Revenue (TTM) | AU$3.58m |
6.4x
P/S Ratio-5.9x
P/E RatioIs IMC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IMC income statement (TTM) | |
|---|---|
| Revenue | AU$3.58m |
| Cost of Revenue | AU$684.13k |
| Gross Profit | AU$2.89m |
| Other Expenses | AU$6.77m |
| Earnings | -AU$3.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.017 |
| Gross Margin | 80.87% |
| Net Profit Margin | -108.52% |
| Debt/Equity Ratio | 0% |
How did IMC perform over the long term?
See historical performance and comparison